Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Open accessAbstract
CONTEXT: In recent years, progress has been made in cancer immunotherapy by the development of drugs acting as modulators of immune checkpoint proteins, such as the cytotoxic T-lymphocyte antigen-4 (CTLA4) and programmed death-1 (PD-1), two co-inhibitory receptors that are expressed on T cells upon activation. These molecules play crucial roles in maintaining immune homeostasis by down-regulating T-cell signaling, thereby preventing unbridled T-cell proliferation while maintaining tolerance to self-antigens, such as tumor-associated antigens. CTLA4 blockade through systemic administration of the CTLA4-blocking antibody ipilimumab was shown to confer significant survival benefit and prolonged stable disease in patients affected by advanced cutaneous melanoma. Other immune checkpoint inhibitors are under clinical evaluation. However, immune checkpoint blockade can lead to the breaking of immune self-tolerance, thereby inducing a novel syndrome of autoimmune/autoinflammatory side effects, designated as "immune-related adverse events," mainly including rash, colitis, hepatitis, and endocrinopathies. DATA ACQUISITION: We searched the medical literature using the words "hypophysitis," "hypopituitarism," "thyroid," "adrenal insufficiency," and "endocrine adverse events" in association with "immune checkpoint inhibitors," "ipilimumab," "tremelimumab," "PD-1," and "PD-1-L." EVIDENCE SYNTHESIS: The spectrum of endocrine disease experienced by patients treated with ipilimumab includes most commonly hypophysitis, more rarely thyroid disease or abnormalities in thyroid function tests, and occasionally primary adrenal insufficiency. Hypophysitis has emerged as a distinctive side effect of CTLA4-blocking antibodies, establishing a new form of autoimmune pituitary disease. This condition, if not promptly recognized, may be life-threatening (due to secondary hypoadrenalism). Hypopituitarism caused by these agents is rarely reversible, and prolonged or lifelong substitutive hormonal treatment is often required. The precise mechanism of injury to the endocrine system triggered by these drugs is yet to be fully elucidated. CONCLUSIONS: Although reports of endocrine side effects caused by cancer immune therapy are abundant, their exact prevalence and mechanism are unclear. Well-designed correlative studies oriented to finding and validating predictive factors of autoimmune toxicity are urgently needed.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Rates of hypothyroidism are 0-40% for nivolumab, 0-11.5% for pembrolizumab, 0-9% for ipilimumab, and 0-5% for tremelimumab.
“Rates of hypothyroidism are 0–40% (nivolumab), 0–11.5% (pembrolizumab), 0–9% (ipilimumab), and 0–5% (tremelimumab) (38).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [38]
Autoimmune thyroiditis is caused by monoclonal antibodies to programmed cell death-1 receptor (nivolumab and pembrolizumab) and to cytotoxic T lymphocyte-associated antigen-4 (ipilimumab, tremelimumab).
“Autoimmune thyroiditis is also caused by monoclonal Ab to programmed cell death-1 receptor (nivolumab and pembrolizumab), and Ab to cytotoxic T lymphocyte-associated antigen-4 (ipilimumab, tremelimumab) (27, 37–39).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [37]
Autoimmune thyroiditis is caused by monoclonal antibodies to programmed cell death-1 receptor (nivolumab and pembrolizumab) and to cytotoxic T lymphocyte-associated antigen-4 (ipilimumab, tremelimumab).
“Autoimmune thyroiditis is also caused by monoclonal Ab to programmed cell death-1 receptor (nivolumab and pembrolizumab), and Ab to cytotoxic T lymphocyte-associated antigen-4 (ipilimumab, tremelimumab) (27, 37–39).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [38]
Anti-CTLA-4 antibodies and anti-PD-1 antibodies induce autoimmune hypophysitis, with rates of 0-17.4% for ipilimumab, 0-2.6% for tremelimumab, 0-0.9% for nivolumab, and 0-1.2% for pembrolizumab.
“Anti-CTLA-4 Ab and anti-PD-1 Ab induce autoimmune hypophysitis (27, 37–39), with rates of 0–17.4% (ipilimumab), 0–2.6% (tremelimumab), 0–0.9% (nivolumab), and 0–1.2% (pembrolizumab) (38).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [37]
In anti-CTLA4-antibody-induced hypophysitis, ACTH- and TSH-deficiency are frequent.
“In anti-CTLA4-Ab-induced hypophysitis, ACTH- and TSH-deficiency are frequent (38).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [38]
Anti-CTLA-4 antibodies and anti-PD-1 antibodies induce autoimmune hypophysitis, with rates of 0-17.4% for ipilimumab, 0-2.6% for tremelimumab, 0-0.9% for nivolumab, and 0-1.2% for pembrolizumab.
“Anti-CTLA-4 Ab and anti-PD-1 Ab induce autoimmune hypophysitis (27, 37–39), with rates of 0–17.4% (ipilimumab), 0–2.6% (tremelimumab), 0–0.9% (nivolumab), and 0–1.2% (pembrolizumab) (38).”
From L-T4 therapy in the presence of pharmacological interferents (2020) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766 · see citing works
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · see citing works
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · see citing works
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,324 · see citing works
Royal, R. E., Levy, C. L., Turner, K. M., Mathur, A., Hughes, M. S., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C.-H., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,266 · see citing works
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195 · see citing works
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091 · see citing works
Cancer immunoediting from immune surveillance to immune escape
Kim, R., Emi, M., & Tanabe, K. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02587.x · Cited by 1,078 · see citing works
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012 · see citing works
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006 · see citing works
Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 999 · see citing works
Beck, K. E., Blansfield, J. A., Tran, K. Q., Feldman, A. L., Hughes, M. S., Royal, R. E., Kammula, U. S., Topalian, S. L., Sherry, R. M., Kleiner, D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5716 · Cited by 833 · see citing works
Yang, J. C., Hughes, M., Kammula, U., Royal, R., Sherry, R. M., Topalian, S. L., Suri, K. B., Levy, C., Allen, T., Mavroukakis, S., et al. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318156e47e · Cited by 697 · see citing works
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
Sharma, P., Wagner, K., Wolchok, J. D., & Allison, J. P. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3153 · Cited by 639 · see citing works
The Emerging Role of CTLA-4 as an Immune Attenuator
Thompson, C. B., & Allison, J. P. (1997) · Immunity · doi:10.1016/s1074-7613(00)80366-0 · Cited by 633 · see citing works
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624 · see citing works
Reck, M., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Lü, H., Cuillerot, J.-M., & Lynch, T. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 608 · see citing works
Caturegli, P., Newschaffer, C. J., Olivi, A., Pomper, M. G., Burger, P. C., & Rose, N. R. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0011 · Cited by 607 · see citing works
Ribas, A., Camacho, L. H., Lopez-Berestein, G., Pavlov, D., Bulanhagui, C. A., Millham, R., Comin-Anduix, B., Reuben, J. M., Seja, E., Parker, C. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.109 · Cited by 591 · see citing works
O'Day, S., Maio, M., Chiarion-Sileni, V., Gajewski, T., Pehamberger, H., Bondarenko, I., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 506 · see citing works
Maker, A. V., Phan, G. Q., Attia, P., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Haworth, L. R., Levy, C. L., et al. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2005.03.536 · Cited by 492 · see citing works
Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
Weber, J. S., O’Day, S., Urba, W., Powderly, J., Nichol, G., Yellin, M., Snively, J., & Hersh, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1927 · Cited by 463 · see citing works
Ku, G. Y., Yuan, J. D., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010) · Cancer · doi:10.1002/cncr.24951 · Cited by 418 · see citing works
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
Zhang, L., Gajewski, T. F., & Kline, J. P. (2009) · Blood · doi:10.1182/blood-2009-03-206672 · Cited by 409 · see citing works
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L. H., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 404 · see citing works
van den Eertwegh, A. J. M., Versluis, J., van den Berg, H. P., Santegoets, S. J. A. M., van Moorselaar, R. J. A., van der Sluis, T. M., Gall, H. E., Harding, T. C., Jooss, K. U., Lowy, I., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70007-4 · Cited by 355 · see citing works
Blansfield, J., Beck, K. E., Tran, K., Yang, J. C., Hughes, M. S., Kammula, U. S., Royal, R. E., Topalian, S. L., Haworth, L. R., Levy, C. L., et al. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000178913.41256.06 · Cited by 352 · see citing works
Ansell, S. M., Hurvitz, S. A., Koenig, P. A., LaPlant, B. R., Kabat, B., Fernando, D., Habermann, T. M., Inwards, D. J., Verma, M., Yamada, R. E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1339 · Cited by 332 · see citing works
Madan, R. A., Mohebtash, M., Arlen, P. M., Vergati, M., Rauckhorst, M., Steinberg, S. M., Tsang, K. Y., Poole, D. J., Parnes, H. L., Wright, J. J., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70006-2 · Cited by 324 · see citing works
Fong, L. H., & Small, E. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.8954 · Cited by 320 · see citing works
Targeting cytotoxic T‐lymphocyte antigen‐4 (CTLA‐4)
O'Day, S. J., Hamid, O., & Urba, W. J. (2007) · Cancer · doi:10.1002/cncr.23086 · Cited by 309 · see citing works
Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
Camacho, L. H., Antonia, S. J., Sosman, J. A., Kirkwood, J. M., Gajewski, T. F., Redman, B. G., Pavlov, D., Bulanhagui, C. A., Bozon, V. A., Gómez-Navarro, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2435 · Cited by 309 · see citing works
Chung, K. Y., Gore, I., Fong, L. H., Venook, A. P., Beck, S. B., Dorazio, P., Criscitiello, P. J., Healey, D. I., Huang, B., Gómez-Navarro, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3994 · Cited by 307 · see citing works
Hersh, E. M., O'Day, S. J., Powderly, J. D., Khan, K. D., Pavlick, A. C., Cranmer, L. D., Samlowski, W. E., Nichol, G. M., Yellin, M. J., & Weber, J. S. (2010) · Investigational New Drugs · doi:10.1007/s10637-009-9376-8 · Cited by 305 · see citing works
Dillard, T. H., Yedinak, C. G., Alumkal, J. J., & Fleseriu, M. (2009) · Pituitary · doi:10.1007/s11102-009-0193-z · Cited by 296 · see citing works
Giacomo, A. M. D., Ascierto, P. A., Pilla, L., Santinami, M., Ferrucci, P. F., Giannarelli, D., Marasco, A., Rivoltini, L., Simeone, E., Nicoletti, S. V. L., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70324-8 · Cited by 285 · see citing works
Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
Ascierto, P. A., Simeone, E., Sznol, M., Fu, Y., & Melero, I. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.008 · Cited by 276 · see citing works
Mumprecht, S., Schürch, C. M., Schwaller, J., Solenthaler, M., & Ochsenbein, A. F. (2009) · Blood · doi:10.1182/blood-2008-09-179697 · Cited by 267 · see citing works
Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma
Maker, A. V., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Hughes, M. S., Yellin, M. J., Haworth, L. R., Levy, C. L., et al. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000208259.73167.58 · Cited by 264 · see citing works
Ralph, C., Elkord, E., Burt, D. J., O'Dwyer, J. F., Austin, E. B., Stern, P. L., Hawkins, R. E., & Thistlethwaite, F. C. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2870 · Cited by 250 · see citing works
Fong, L. H., Kwek, S. S., O’Brien, S., Kavanagh, B., McNeel, D. G., WEINBERG, V. K., Lin, A., Rosenberg, J. E., Ryan, C. J., Rini, B. I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3529 · Cited by 245 · see citing works
The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications
Giacomo, A. M. D., BIAGIOLI, M., & Maio, M. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.007 · Cited by 244 · see citing works
Kirkwood, J. M., Lorigan, P. C., Hersey, P., Hauschild, A., Robert, C., McDermott, D. F., Marshall, M. A., Gómez-Navarro, J., Liang, J. Q., & Bulanhagui, C. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2033 · Cited by 241 · see citing works
Metastases to the pituitary gland
Fassett, D. R., & Couldwell, W. T. (2004) · Neurosurgical FOCUS · doi:10.3171/foc.2004.16.4.9 · Cited by 236 · see citing works
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00649.x · Cited by 228 · see citing works
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy
Torino, F., Corsello, S. M., Longo, R., Barnabei, A., & Gasparini, G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.4 · Cited by 207 · see citing works
Self-citationThyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Min, L., Vaidya, A., & Becker, C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0833 · Cited by 179 · see citing works
Pituitary autoimmunity: 30 years later
Caturegli, P., Lupi, I., Landek‐Salgado, M. A., Kimura, H. J., & Rose, N. R. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.04.016 · Cited by 174 · see citing works
Kaehler, K. C., Piel, S., Livingstone, E., Schilling, B., Hauschild, A., & Schadendorf, D. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.003 · Cited by 170 · see citing works
Thyroid Dysfunction from Antineoplastic Agents
Hamnvik, O. R., Larsen, P. R., & Marqusee, E. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr373 · Cited by 165 · see citing works
Melanoma drug wins US approval
Ledford, H. K. (2011) · Nature · doi:10.1038/471561a · Cited by 164 · see citing works
Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors
Tarhini, A. A., Lo, E., & Minor, D. R. (2010) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0865 · Cited by 159 · see citing works
Dillman, R. O. (2011) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2010.0902 · Cited by 156 · see citing works
Ribas, A., Hauschild, A., Kefford, R. F., Punt, C. J. A., Haanen, J. B. A. G., Mármol, M., Garbe, C., Gómez-Navarro, J., Pavlov, D., & Marshall, M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.lba9011 · Cited by 155 · see citing works
Role of Cytokines in the Pathogenesis and Suppression of Thyroid Autoimmunity
Ganesh, B. B., Bhattacharya, P., Gopisetty, A., & Prabhakar, B. S. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0049 · Cited by 153 · see citing works
Improving cancer immunotherapy by targeting tumor-induced immune suppression
Stewart, T. J., & Smyth, M. J. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9280-5 · Cited by 152 · see citing works
Genetic and epigenetic mechanisms in thyroid autoimmunity
Hasham, A., & Tomer, Y. (2012) · Immunologic Research · doi:10.1007/s12026-012-8302-x · Cited by 144 · see citing works
Johnston, R. L., Lutzky, J., Chodhry, A., & Barkin, J. S. (2009) · Digestive Diseases and Sciences · doi:10.1007/s10620-008-0641-z · Cited by 135 · see citing works
Wolchok, J. D., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Schadendorf, D., de Pril, V., Heller, K. N., Chen, T., Ibrahim, R. A., et al. (2010) · PubMed Central · Cited by 133 · see citing works
Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
Borodic, G., Hinkle, D. M., & Cia, Y. (2011) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0b013e3181ef72a1 · Cited by 120 · see citing works
Juszczak, A., Gupta, A., Karavitaki, N., Middleton, M. R., & Grossman, A. B. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0167 · Cited by 117 · see citing works
Ipilimumab-Induced Hypophysitis: MR Imaging Findings
Carpenter, K. J., Murtagh, R. D., Lilienfeld, H. S., et al. (2009) · American Journal of Neuroradiology · doi:10.3174/ajnr.a1623 · Cited by 115 · see citing works
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
Weber, J. S. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-16 · Cited by 103 · see citing works
Klein, O., Ebert, L. M., Nicholaou, T., Browning, J., Russell, S. E., Zuber, M., Jackson, H. M., Dimopoulos, N., Tan, B. S., Hoos, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2424 · Cited by 100 · see citing works
Weijl, N. I., Harst, D. V. D., Brand, A., Kooy, Y. M. C., Luxemburg, S. V., Schroder, J., Lentjes, E. G. W. M., ROOD, J. J. V., Cleton, F. J., & Osanto, S. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.7.1376 · Cited by 99 · see citing works
Immunopathology of Primary Hypophysitis
Gutenberg, A., Buslei, R., Fahlbusch, R., et al. (2005) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000149707.12335.8e · Cited by 87 · see citing works
Giacomo, A. M. D., Danielli, R., Calabrò, L., Bertocci, E., Nannicini, C., Giannarelli, D., Balestrazzi, A., Vigni, F., Riversi, V., Miracco, C., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0958-2 · Cited by 81 · see citing works
Torino, F., Barnabei, A., Vecchis, L. D., Salvatori, R., & Corsello, S. M. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0404 · Cited by 79 · see citing works
Self-citationIpilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade
Boasberg, P. D., Hamid, O., & O'Day, S. J. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.004 · Cited by 73 · see citing works
Thyroid dysfunction associated with immunotherapy for patients with cancer
Schwartzentruber, D. J., White, D. E., ZWEIG, M. H., Weintraub, B. D., & Rosenberg, S. A. (1991) · Cancer · doi:10.1002/1097-0142(19911201)68:11 · Cited by 73 · see citing works
Thyroiditis after treatment with interleukin-2 and interferon α-2a
Pichert, G., Jost, L. M., Zöbeli, L., Odermatt, B., Pedia, G., & Stahel, R. A. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.237 · Cited by 72 · see citing works
The Endocrine Effects of Nonhormonal Antineoplastic Therapy
Yeung, S. J., Chiu, A. C., Vassilopoulou‐Sellin, R., & Gagel, R. F. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.2.0328 · Cited by 72 · see citing works
Glucocorticoids Do Not Inhibit Antitumor Activity of Activated CD8+ T Cells
Hinrichs, C. S., Palmer, D. C., Rosenberg, S. A., & Restifo, N. P. (2005) · Journal of Immunotherapy · doi:10.1097/01.cji.0000177999.95831.7b · Cited by 71 · see citing works
How reliably can autoimmune hypophysitis be diagnosed without pituitary biopsy
Howlett, T. A., Levy, M. J., & Robertson, I. J. A. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03765.x · Cited by 70 · see citing works
Vialettes, B., Guillerand, M. A., Viens, P., Stoppa, A., Baume, D., Sauvan, R., Pasquier, J., Marco, M. S., Olive, D., & Maraninchi, D. (1993) · European Journal of Endocrinology · doi:10.1530/acta.0.1290031 · Cited by 65 · see citing works
Hanaizi, Z., van Zwieten‐Boot, B., Calvo, G., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.09.018 · Cited by 64 · see citing works
Kragel, A. H., Travis, W. D., Feinberg, L., et al. (1990) · Human Pathology · doi:10.1016/0046-8177(90)90005-p · Cited by 63 · see citing works
Min, L., Vaidya, A., & Becker, C. (2011) · Endocrine Practice · doi:10.4158/ep11273.or · Cited by 62 · see citing works
Hodi, F. S., Friedlander, P. A., Atkins, M. B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.8511 · Cited by 51 · see citing works
Acute Thyroid Dysfunction (Thyroiditis) after Therapy with Interleukin-2
Vassilopoulou‐Sellin, R., Sella, A., Dexeus, F. H., et al. (1992) · Hormone and Metabolic Research · doi:10.1055/s-2007-1003353 · Cited by 46 · see citing works
Sauter, N. P., Atkins, M. B., Mier, J. W., et al. (1992) · The American Journal of Medicine · doi:10.1016/0002-9343(92)90278-j · Cited by 46 · see citing works
Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review
Goglia, U., Ferone, D., Sidoti, M., Spaziante, R., Dadati, P., Ravetti, J.-L., Villa, G., Bodei, L., Paganelli, G., Minuto, F. M., et al. (2007) · Pituitary · doi:10.1007/s11102-007-0038-6 · Cited by 42 · see citing works
T regulatory cells distinguish two types of primary hypophysitis
Mirocha, S., Elagin, R. B., Salamat, S. M., & Jaume, J. C. (2008) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2008.03828.x · Cited by 40 · see citing works
Weber, J. S., Targan, S. R., Scotland, R., Snively, J., Garcia, M., Yellin, M. J., Fischkoff, S. A., & Nichol, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.2510 · Cited by 38 · see citing works
Current Experience With CTLA4-blocking Monoclonal Antibodies for the Treatment of Solid Tumors
Agarwala, S. S., & Ribas, A. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181dcd260 · Cited by 36 · see citing works
Ridruejo, E., Christensen, A. F., & Mandό, O. G. (2006) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200606000-00019 · Cited by 35 · see citing works
Reversible hypopituitarism after interferonalfa therapy
Sakane, N., Yoshida, T., Yoshioka, K., Umekawa, T., Kondo, M., & Shimatsu, A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90950-8 · Cited by 33 · see citing works
Interferon-induced hypopituitarism
Concha, L. B., Carlson, H. E., Heimann, A., Lake‐Bakaar, G., & Paal, A. F. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01323-2 · Cited by 32 · see citing works
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823261db · Cited by 26 · see citing works
Granulomatous Adenohypophysitis after Interferon and Ribavirin Therapy
Tebben, P. J., Atkinson, J. L. D., Scheithauer, B. W., & Erickson, D. Z. (2007) · Endocrine Practice · doi:10.4158/ep.13.2.169 · Cited by 26 · see citing works
Peppa, Μ., Papaxoinis, G., Xiros, N., et al. (2009) · Clinical Breast Cancer · doi:10.3816/cbc.2009.n.047 · Cited by 23 · see citing works
Metastatic renal cell carcinoma to the pituitary presenting with hyperprolactinemia
Basaria, S., Westra, W. H., Brem, H., et al. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345294 · Cited by 22 · see citing works
Managing Immune-Related Adverse Events to Ipilimumab: A Nurse's Guide
Rubin, K. M. (2012) · Clinical journal of oncology nursing · doi:10.1188/12.cjon.e69-e75 · Cited by 20 · see citing works
Panhypopituitarism in association with interferon-alpha treatment.
Chan, J. C. N., & Cockram, C. S. (2004) · PubMed · Cited by 19 · see citing works
Bronchial carcinoid tumors metastatic to the sella turcica and review of the literature
Moshkin, O., Rotondo, F., Scheithauer, B. W., et al. (2012) · Pituitary · doi:10.1007/s11102-012-0388-6 · Cited by 16 · see citing works
Alacacıoğlu, A., Öztop, İ., Fidan, F., et al. (2008) · Tumori Journal · doi:10.1177/030089160809400524 · Cited by 15 · see citing works
Hamid, O., Hwu, W., Richards, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.8508 · Cited by 14 · see citing works
Does Genomic Imprinting Play a Role in Autoimmunity?
Camprubí, C., & Monk, D. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-8216-2_8 · Cited by 12 · see citing works
Induction of Experimental Autoimmune Hypophysitis in SJL Mice
Landek‐Salgado, M. A., Tzou, S., Kimura, H. J., et al. (2010) · Journal of Visualized Experiments · doi:10.3791/2182 · Cited by 4 · see citing works
Induction of Experimental Autoimmune Hypophysitis in SJL Mice
Landek‐Salgado, M. A., Tzou, S.-C., Kimura, H. J., et al. (2010) · Journal of Visualized Experiments · doi:10.3791/2182-v · Cited by 2 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Lebbe ´C, O'Day S, Chiarion Sileni V, et al. Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma. In: Proceedings from Perspectives in Melanoma XII; October 2-4, 2008; Schev- eningen, the Hague, the Netherlands. Abstract O-015.
- Juszczak A, Gupta A, Karavitaki N, Middleton MR, Grossman AB. Ipilimumab: a novel immunomodulating therapy causing autoim- mune hypophysitis: a case report and review. Eur J Endocrinol. 2012;167:1-5.
Cited by
Sorted by citations
on behalf of the Society for Immunotherapy of Cancer Toxicity Management Working Group, Puzanov, I., Diab, A., Abdallah, K., Bingham, C. O., Brogdon, C., Dadu, R., Hamad, L., Kim, S., Lacouture, M. E., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0300-z · Cited by 1,992 · see citing works
Management of toxicities of immune checkpoint inhibitors
Spain, L., Diem, S., & Larkin, J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.001 · Cited by 854 · see citing works
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715 · see citing works
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685 · see citing works
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439 · see citing works
de Filette, J., Andreescu, C., Cools, F., Bravenboer, B., & Velkeniers, B. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0843-3366 · Cited by 381 · see citing works
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Faje, A. (2016) · Pituitary · doi:10.1007/s11102-015-0671-4 · Cited by 326 · see citing works
Delivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278 · see citing works
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244 · see citing works
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Yamauchi, I., Sakane, Y., Fukuda, Y., Fujii, T., Taura, D., Hirata, M., Hirota, K., Ueda, Y., Kanai, Y., Yamashita, Y., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0562 · Cited by 169 · see citing works
Kimbara, S., Fujiwara, Y., Iwama, S., Ohashi, K., Kuchiba, A., Arima, H., Yamazaki, N., Kitano, S., Yamamoto, N., & Ohe, Y. (2018) · Cancer Science · doi:10.1111/cas.13800 · Cited by 158 · see citing works
Burch, H. B. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1901214 · Cited by 164 · see citing works
Scott, E. S., Long, G. V., Guminski, A., Clifton-Bligh, R. J., Menzies, A. M., & Tsang, V. H. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0810 · Cited by 142 · see citing works
French Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140 · see citing works
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117 · see citing works
Self-citationAutoimmune endocrine dysfunctions associated with cancer immunotherapies
Ferrari, S. M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M. R., Baldini, E., Ulisse, S., Marone, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102560 · Cited by 107 · see citing works
Immune-mediated drug-induced liver injury: immunogenetics and experimental models
Gerussi, A., Natalini, A., Antonangeli, F., Mancuso, C., Agostinetto, E., Barisani, D., Di Rosa, F., Andrade, R., & Invernizzi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094557 · Cited by 87 · see citing works
Fukuoka, H. (2015) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.011 · Cited by 50 · see citing works
Abdel-Rahman, O., & Fouad, M. (2016) · Immunotherapy · doi:10.2217/imt-2015-0020 · Cited by 46 · see citing works
Less known aspects of central hypothyroidism: Part 1- Acquired etiologies
Benvenga, S., Klose, M., Vita, R., & Feldt-Rasmussen, U. (2018) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2018.09.003 · Cited by 19 · see citing works
L-T4 therapy in the presence of pharmacological interferents
Benvenga, S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.607446 · Cited by 13 · see citing works
Yajima, K., & Akise, Y. (2019) · Case Reports in Endocrinology · doi:10.1155/2019/2314032 · Cited by 13 · see citing works
- Authors
- Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Instituto Nazionale Tumori Regina Elena (IT)
- Azienda Ospedaliera Sant'Andrea (IT)
- Department of Systems Medicine (L.D.V., F.T.), Chair of Medical Oncology, Tor Vergata University of Rome, 00133 Rome, Italy
- Johns Hopkins University (US)
- University of Rome Tor Vergata (IT)
- Corresponding author
- Corsello, Salvatore Maria
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-04-01
- Volume
- 98
- Issue
- 4
- Pages
- 1361-1375
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2022073464
- Cited by
- 403
- References
- 106
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 11 · 2023: 18 · 2022: 29 · 2021: 43 · 2020: 45 · 2019: 47 · 2018: 44 · 2017: 52 · 2016: 41 · 2015: 25 · 2014: 23 · 2013: 8
- FWCI
- 17.30
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion, other-oa)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- immune checkpoint inhibitors, endocrine adverse events, hypophysitis, hypopituitarism, CTLA-4 blockade, ipilimumab, tremelimumab, anti-PD-1 therapy, autoimmune pituitary disease, adrenal insufficiency, thyroid dysfunction, immune-related adverse events, cancer immunotherapy
- MeSH terms
- Antibodies, Monoclonal, Antineoplastic Agents, Endocrine System Diseases, Endocrine System, Humans, Immunotherapy, Neoplasms, Cell Cycle Checkpoints, CTLA-4 Antigen, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
